Uncategorized Archives - Page 16 of 134

TuesdayJan 30, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline

An innovative combination of insights from physics, chemistry, materials science, and biology positions the new nanomedicine CNM-Au8(R) to address neurodegenerative disease, such as ALS, from a new angle The FDA has offered guidance to Clene on CNM-Au8’s application, with discussions ongoing for the possibility of accelerated approval on the basis of improved survival, biomarker, and clinical efficacy data in people living with ALS With plans to move forward on many fronts for the clinical development of CNM-Au8, 2024 looks bright for Clene Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

TuesdayJan 23, 2024 9:45 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary AgLAB: Breakthrough Technology For Ag-Distillers

Astrotech subsidiary AgLAB demonstrates the capability of significant improvements in yields for large scale producers of hemp and cannabis CBD-THC oils using breakthrough mass spectrometry technology The company’s AgLAB 1000-D2(TM) mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP(TM)”) allows large-scale distillers to analyze oils during processing, and make real-time adjustments to boost yields and potencies Field trials resulted in improved ending-weight yields by an average of 30%, which can translate into bottom-line profits Astrotech presented the AgLAB Maximum Value Process at last year’s MJBizCon in November, it is the premier global hemp and cannabis business conference and…

MondayJan 22, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment

Significant improvements in both vision and cognition, sustained over three years, were reported with CNM-Au8 treatment in results from the long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis Michael Barnett, a key clinical advisor, hailed the results, observed long term and over and above background therapy. as “unprecedented” A drug that may halt MS disease progression or improve function on top of standard-of-care MS therapies would represent a significant milestone in drug development for this disease Clene will present the full clinical results for the LTE at the ninth annual Americas Committee for…

TuesdayJan 16, 2024 11:15 am

InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD. The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 4–15 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of…

MondayJan 08, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Announces New Mass Spectrometry Technology Application for Chemical Manufacturing and Introduces the Pro-Control Subsidiary

Astrotech’s newest subsidiary, Pro-Control, will use the company’s mass spectrometer technology to improve purity, and yields of distilled chemicals Pro-Control delivers value by improving lost yields and delivering found profits directly to the bottom line with little, which the company believes will lead to an overall increase in profitability Astrotech believes that the Pro-Control MVP has the ability to routinely improve yields from 20% to 30% The company is introducing its proprietary ATi Mass Spectrometer Technology into the vast chemical manufacturing and process control markets Astrotech (NASDAQ: ASTC), is an instrumentation company that is focused on commercializing its proprietary ATi…

MondayJan 08, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics in May 2023 announced patent and trademark applications for its ImmunePrep commercialization platform In October 2022, the company announced patent and trademark applications for ChemoPrep and ChemoPure to enhance chemotherapy and reduce toxicity Sigyn Therapeutics in September 2022 announced plans to conduct first-in-human feasibility studies in end-stage renal disease patients In August 2022, the company commenced trading on the OTCQB Venture Market Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy(TM) to address pathogen-associated inflammatory disorders, the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies,…

TuesdayJan 02, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials

Clene Inc., a late clinical-stage biopharmaceutical company focused on developing solutions that improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, recently announced the publication of a peer-reviewed article The article describes results from two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8, the company’s lead drug candidate, on brain energy metabolite levels in participants with Parkinson’s Disease and Multiple Sclerosis, respectively Researchers measured key brain metabolites, such as NADH and NAD+, which are involved in neuronal energy production, utilization, and maintenance, for changes from baseline with daily, oral treatment of CNM-Au8 over…

TuesdayDec 19, 2023 9:00 am

Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes

We all know that a diet high in fiber is good for us, with studies suggesting that consuming a high-fiber diet can lower an individual’s risk for some cancers. Now, researchers are looking into whether a high-fiber diet can help patients with cancer fight a cancer diagnosis by boosting immunotherapy effectiveness. Previous research involving melanoma patients already determined that those with diets that were high in fiber responded better to immunotherapy. At the forefront of this latest research is assistant professor Brendan Guercio from the Wilmot Cancer Institute. Guercio has specialized in hematology/oncology and works as a medical oncologist who…

MondayDec 18, 2023 10:30 am

How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health The company’s lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders (“ND”), namely amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”) Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises…

MondayDec 18, 2023 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

The CDC estimates 1 out of 36 children in the United States have been diagnosed with Autism Spectrum Disorder – with a therapeutic market potential of $3.42 billion by 2030 PaxMedica’s mission is to help eliminate, reduce, or modulate the troublesome aspects of ASD, an unmet medical need in the industry CEO Howard Weisman shared important updates and achievements in the company’s pipeline, financial outlook, and future vision In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline

Astrotech Corp. (NASDAQ: ASTC) Subsidiary AgLAB: Breakthrough Technology For Ag-Distillers

Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment

InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

Astrotech Corp. (NASDAQ: ASTC) Announces New Mass Spectrometry Technology Application for Chemical Manufacturing and Introduces the Pro-Control Subsidiary

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials

Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes

How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search